Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monalizumab - Innate Pharma

Drug Profile

Monalizumab - Innate Pharma

Alternative Names: Anti-NKG2A; IPH-22; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100

Latest Information Update: 29 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer AstraZeneca; Innate Pharma; Istituto Clinico Humanitas; NCIC Clinical Trials Group; Netherlands Cancer Institute; Novo Nordisk
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily C antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Bladder cancer; HER2 positive breast cancer; Myelodysplastic syndromes; Small cell lung cancer; Squamous cell cancer
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • No development reported Haematological malignancies
  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 12 Dec 2024 Phase-II clinical trials in Bladder cancer (Combination therapy) in USA (IV) (NCT06503614)
  • 09 Sep 2024 Efficacy and adverse event data from the phase II NeoCOAST 2 trial released by Innate Pharma
  • 31 May 2024 Adverse events and efficacy data from a phase II COAST trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top